Table 2.

Results of quantitative Chip/Chip/SRM measurements for PSA protein added to human female plasma (i) prior to immunodepletion of albumin and IgG^a with LOQ indicated in bold; (ii) recovery of PSA after immunodepletion step only as determined by ELISA; and (iii) Chip/Chip/SRM measurements for PSA protein added to female plasma after immunodepletion with the LOQ specified in bold.

				Target ng/mL
Protein	Proteotypic peptide	Q1 → Q3	Quantitative measurements	0.25	0.50	1.0	2.5	5.0	25	50
(i)	PSA added prior to immunodepletion/dPC
PSA	IVGGWECamcEK	539.7 → 866.3	Calculated ng/mL	NSD	0.10	0.29	1.1	2.6	19	35
			% CV	NSD	137	13	18	12	8.2	10
			% Recoveryb	NSD	20	29	42	53	76	70
PSA	LSEPAELTDAVK	636.8 → 943.5	Calculated ng/mL	NSD	0.13	0.36	1.2	2.7	15	32
			% CV	NSD	132	19	14	18	11	12
			% Recoveryb	NSD	20	36	47	55	60	64
(ii)	PSA after immunodepletion (without dPC), % recovery measured by ELISA (n = 2)
	Total PSA measured			N/A	N/A	N/A	41	65	71	65
(iii)	PSA added after immunodepletion/dPC
PSA	IVGGWECamcEK	539.7 → 866.3	Calculated ng/mL	0.11	0.21	1.0	2.8	4.1	N/A	N/A
			% CV	122	2.8	10.0	9.9	9.6
			% Recoveryb	44	41	101	110	81
PSA	LSEPAELTDAVK	636.8 → 943.5	Calculated ng/mL	0.20	0.24	1.0	2.6	4.1	N/A	N/A
			% CV	115	22	16	13	11
			% Recoveryb	80	48	98	103	82

^aSample Preparations and SRM experiments were performed in duplicate for a total of four replicates (n = 4).

^b% Recovery = (calculated (ng/mL)/target (ng/mL) × 100.

N/A = sample were not investigated.

NSD = no single detected.